Karyopharm Therapeutics
KPTI
136 hedge funds and large institutions have $1.31B invested in Karyopharm Therapeutics in 2020 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 56 increasing their positions, 37 reducing their positions, and 35 closing their positions.
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
51% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 37
16% more capital invested
Capital invested by funds: $1.13B → $1.31B (+$177M)
2% more call options, than puts
Call options by funds: $22.2M | Put options by funds: $21.7M
0.82% more ownership
Funds ownership: 93.89% → 94.71% (+0.82%)
7% less funds holding
Funds holding: 146 → 136 (-10)
20% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$59.8M |
| 2 |
Alkeon Capital Management
New York
|
+$37.5M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$24.5M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$22.5M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
+$20.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$14.6M |
| 2 |
O
OrbiMed
New York
|
-$11.9M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$11.3M |
| 4 |
Two Sigma Investments
New York
|
-$5.81M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$5.64M |
KPTI Hedge Fund Activity: Q1 2020 in Review
136 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2020, worth a combined $1.31B — up 16% from $1.13B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of KPTI and 28 opened new positions — a net loss of 7 holders — while 37 trimmed existing stakes and 56 added.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $59.8M. The largest seller was Federated Hermes, cutting an estimated $14.6M.
- 136 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2020, down from 146 in Q4 2019.
- Funds reported $1.31B of Karyopharm Therapeutics stock for Q1 2020, up 16% quarter-over-quarter.
- 28 funds opened new Karyopharm Therapeutics positions in Q1 2020 and 35 closed out, a net change of -7 holders.
- The largest Karyopharm Therapeutics buyer in Q1 2020 was Janus Henderson Group, an estimated $59.8M added.
- The largest Karyopharm Therapeutics seller in Q1 2020 was Federated Hermes, an estimated $14.6M sold.
Based on aggregated 13F filings for Q1 2020.